Cited by 697RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

In vivo imaging of siRNA delivery and silencing in tumors

Medarova, Zdravka, Pham, Wellington, Farrar, Christian, Petkova, Victoria, Moore, Anna·2007·Nature Medicine

Abstract

With the increased potential of RNA interference (RNAi) as a therapeutic strategy, new noninvasive methods for detection of siRNA delivery and silencing are urgently needed. Here we describe the development of dual-purpose probes for in vivo transfer of siRNA and the simultaneous imaging of its accumulation in tumors by high-resolution magnetic resonance imaging (MRI) and near-infrared in vivo optical imaging (NIRF). These probes consisted of magnetic nanoparticles labeled with a near-infrared dye and covalently linked to siRNA molecules specific for model or therapeutic targets. Additionally, these nanoparticles were modified with a membrane translocation peptide for intracellular delivery. We show the feasibility of in vivo tracking of tumor uptake of these probes by MRI and optical imaging in two separate tumor models. We also used proof-of-principle optical imaging to corroborate the efficiency of the silencing process. These studies represent the first step toward the advancement of siRNA delivery and imaging strategies, essential for cancer therapeutic product development and optimization.

Integrity signals

Registry

Crossref · 10.1038/nm1486

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Medarova et al. achieved substantial silencing of GFP and survivin in tumors using a SPION-based theranostic nanoplatform for siRNA delivery, comparable or superior to previous studies.

    “They achieved substantial silencing (of both GFP and survivin) in tumors, which was comparable or superior to previous published studies. This study thereby provided pioneering proof-of-concept for a SPION-based theranostic nanoplatform for siRNA delivery [239].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A.
Affiliations
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Moore, Anna
Venue
Nature Medicine
Published
2007-02-25
Volume
13
Issue
3
Pages
372-377
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2138436760
Cited by
697
References
35
Citations by year
2026: 5 · 2025: 12 · 2024: 15 · 2023: 13 · 2022: 15 · 2021: 20 · 2020: 20 · 2019: 19 · 2018: 24 · 2017: 34 · 2016: 41 · 2015: 36 · 2014: 53 · 2013: 65 · 2012: 63
FWCI
25.94
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (K25AG029415)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
siRNA delivery, RNA interference, in vivo imaging, magnetic nanoparticles, tumor targeting, intracellular delivery, gene silencing, tumor uptake, cancer therapeutics
MeSH terms
Adenocarcinoma, Animals, Humans, Magnetic Resonance Imaging, Colorectal Neoplasms, Molecular Probes, Spectroscopy, Near-Infrared, Gene Silencing, RNA, Small Interfering, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review